VCREATE, INC

VCREATE, INC specializes in early-stage biomedical research and development focused on novel immunotherapeutic platforms, particularly in the domain of T-cell receptor engineering for pediatric oncology. Their technical expertise centers on translational immunology, antigen discovery, and preclinical validation of T-cell receptor-based therapies for aggressive hematologic malignancies such as pediatric acute myeloid leukemia. The company leverages molecular biology, cellular immunology, and bioinformatics to identify and optimize high-affinity T-cell receptors with therapeutic potential, distinguishing itself through its focus on rare pediatric cancers and early-phase innovation under SBIR frameworks. Their work bridges laboratory discovery and clinical translation, emphasizing target specificity, safety profiling, and mechanistic validation in immune cell engineering. VCREATE has demonstrated direct engagement with the Department of Health and Human Services, primarily through SBIR programs that fund high-risk, high-reward biomedical innovations. Their relationship with HHS reflects a focus on early-stage, non-clinical research aimed at addressing unmet medical needs in pediatric oncology, suggesting alignment with NIH and BARDA priorities in precision immunotherapy development. The contractor’s primary NAICS classification under 541715 reflects deep specialization in physical and life sciences R&D outside biotechnology and nanotechnology, placing them squarely in the domain of fundamental immunological research and therapeutic target validation. They operate in a niche market segment focused on T-cell receptor discovery and preclinical development for rare pediatric cancers, positioning themselves as a specialized research partner for government-funded early-phase oncology programs. VCREATE, INC is a small business structured as a 2L entity, headquartered in Menlo Park, California, with no publicly disclosed federal certifications. Their geographic presence in the Bay Area supports access to academic research institutions and biotech ecosystems, enhancing their capacity to execute complex, hypothesis-driven R&D projects under federal grants.